BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

VNDA upcoming catalysts

Vanda Pharmaceuticals: 2 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (2 Phase 3), 1 upcoming FDA decision event(s), and in the last 12 months 5 readout(s) and 2 FDA event(s). Subscribe to VNDA (.ics).

Drugs: Tradipitant, VQW-765

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
2026-12-12PDUFA date (company-disclosed)pendingVanda Pharmaceuticals Inc. VNDAimsidolimabPDUFA December 12, 2026 - Vanda Pharmaceuticals Inc. (imsidolimab)

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3Vanda Pharmaceuticals VNDANCT07221578 Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderSocial Anxiety Disorder (SAD)active not recruiting500
2026-12-01 est.P3Vanda Pharmaceuticals VNDANCT07446439 A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseNausea and Vomiting; Obesityrecruiting280

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-02-20FDA approvalapprovedVANDA PHARMS INC VNDABYSANTIApproved 2026-02-20: BYSANTI (NDA220358 ORIG1)
2025-12-30FDA approvalapprovedVANDA PHARMS INC VNDANEREUSApproved 2025-12-30: NEREUS (NDA220152 ORIG1)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10 est.P2Vanda Pharmaceuticals VNDANCT07090161 Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionHypertension; Uncontrolled Hypertensionrecruiting240
2026-09-04P3Vanda Pharmaceuticals VNDANCT04652882 Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorderscompleted43
2026-09 est.P2Vanda Pharmaceuticals VNDANCT07179055 An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeDry Eyerecruiting160
2026-09 est.P2Vanda Pharmaceuticals VNDANCT07065773 Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe OnychomycosisOnychomycosis of Toenailactive not recruiting50
2026-03-30P3Vanda Pharmaceuticals VNDANCT06836557 Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisIdiopathic Gastroparesis; Diabetic Gastroparesis; Gastroparesiscompleted17

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.